US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Media News - August 3, 2021 Category: Pharmaceuticals Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Investor Update - August 3, 2021 Category: Pharmaceuticals Source Type: news

Neoadjuvant Chemoimmunotherapy in Resectable NSCLC Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
Is the use of neoadjuvant immunotherapy combined with chemotherapy a safe and effective therapeutic option for patients with resectable non-small cell lung cancer?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

NonSmall Cell Lung Cancer Vs Small Cell Cancer
What Is the Non-Small Cell Lung Cancer Vs. Small Cell Prognosis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 2, 2021 Category: General Medicine Source Type: news

How Aggressive Is Non-Small Cell Lung Cancer?
Title: How Aggressive Is Non-Small Cell Lung Cancer?Category: Diseases and ConditionsCreated: 7/30/2021 12:00:00 AMLast Editorial Review: 7/30/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 30, 2021 Category: Cancer & Oncology Source Type: news

Which Is More Aggressive, SCLC or NSCLC?
Title: Which Is More Aggressive, SCLC or NSCLC?Category: Diseases and ConditionsCreated: 7/30/2021 12:00:00 AMLast Editorial Review: 7/30/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 30, 2021 Category: Cancer & Oncology Source Type: news

Smoking Cessation After NSCLC Diagnosis Cuts Mortality Risk
Risks for all - cause mortality, cancer - specific mortality, disease progression reduced for those quitting after diagnosis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 27, 2021 Category: Cancer & Oncology Tags: Oncology, Pulmonology, Journal, Source Type: news

Smoking Cessation After NSCLC Diagnosis Cuts Mortality Risk
TUESDAY, July 27, 2021 -- For patients with non-small cell lung cancer (NSCLC), smoking cessation after diagnosis is associated with a reduced risk for all-cause mortality, cancer-specific mortality, and disease progression, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 27, 2021 Category: Pharmaceuticals Source Type: news

Researcher Hopes to Improve Tumor Treating Fields for Mesothelioma
Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and Drug Administration’s approval of the treatment in 2019. He also knows the therapy is only scratching the surface of its vast potential and could be even more effective. He wants to help improve it. D’Incalci, a heralded biomedical science professor at Humanitas University in Milan, Italy, has begun a study exploring various drug combinations that could have a positive, synergistic effect with Tumor Treating Fields for mesothelioma. “There m...
Source: Asbestos and Mesothelioma News - July 27, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

RSNA to launch imaging AI certificate program
The RSNA is launching a certificate program in artificial intelligence (AI...Read more on AuntMinnie.comRelated Reading: RSNA AI challenge focuses on brain tumors RSNA Research and Education Foundation awards $3M in grants RSNA R&E grant study identifies new biomarker for NSCLC RSNA issues call for abstracts for 2021 meeting Top healthcare trends on display at RSNA 2020 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 21, 2021 Category: Radiology Source Type: news

New Drug Combination Shows Promise for Peritoneal Mesothelioma
Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling a gaping void that exists today. The immunotherapy drug combination of Tecentriq and Avastin, known generically as atezolizumab and bevacizumab, respectively, showed unusual efficacy in a recent study of 20 patients with this rare cancer. Although some patients have previously found significant success and extended survival with the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combination, or HIPEC, those with unresectable disease ha...
Source: Asbestos and Mesothelioma News - July 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Study identifies MET amplification as driver for some non-small cell lung cancers
(University of Colorado Anschutz Medical Campus) A study led by CU Cancer Center member D. Ross Camidge, MD, PhD, has helped define MET amplification as an actionable driver for some non-small cell lung cancers (NSCLC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 20, 2021 Category: Cancer & Oncology Source Type: news

Adding Ipilimumab to Nivolumab No Better in Pretreated Squamous NSCLC
No difference in overall survival seen with nivolumab plus ipilimumab, nivolumab alone for advanced, chemotherapy - pretreated disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 16, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

Adding Ipilimumab to Nivolumab No Better in Pretreated Squamous NSCLC
FRIDAY, July 16, 2021 -- For patients with advanced, chemotherapy-pretreated, immune checkpoint inhibitor-naive squamous (Sq) non-small cell lung cancer (NSCLC), ipilimumab added to nivolumab does not improve outcomes versus nivolumab alone,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 16, 2021 Category: Pharmaceuticals Source Type: news

RSNA AI challenge focuses on brain tumors
The RSNA, the American Society of Neuroradiology, and the Medical Image Computin...Read more on AuntMinnie.comRelated Reading: RSNA Research and Education Foundation awards $3M in grants RSNA announces 2021 meeting highlights RSNA announces MIDRC funding program RSNA R&E grant study identifies new biomarker for NSCLC SIIM, RSNA, others partner on COVID-19 AI challenge (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 14, 2021 Category: Radiology Source Type: news

NSCLC and Melanoma Lead Continuing Fall in US Cancer Death Rates NSCLC and Melanoma Lead Continuing Fall in US Cancer Death Rates
Cancer death rates in the US continue to decline overall for many common cancers in both men and women, especially non –small cell lung cancer (NSCLC) and melanoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASCO Data Present'Clear Roadmap' to Treat Locally Advanced NSCLC ASCO Data Present'Clear Roadmap' to Treat Locally Advanced NSCLC
' These studies point to the need for multimodality therapy for the patients with locally advanced NSCLC,'says Dr Mark Kris.Medscape Oncology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - July 9, 2021 Category: Radiology Tags: Hematology-Oncology Commentary Source Type: news

Radiomics enables 'one-stop' test for lung cancer and heart disease
Radiomics analysis of low-dose CT lung screening exams can be used to stratif...Read more on AuntMinnie.comRelated Reading: AI may predict heart disease risk on chest x-ray AI predicts cardiovascular risk on LDCT lung cancer screening CT radiomics predicts survival in NSCLC patients CT radiomics classifies small nodules found in CT lung screening CT radiomics characterizes complex cystic renal lesions (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 7, 2021 Category: Radiology Source Type: news

Combining Radiotherapy With Targeted Therapies in NSCLC Combining Radiotherapy With Targeted Therapies in NSCLC
Combining radiotherapy with targeted agents could be a promising therapeutic strategy for non-small cell lung cancer.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Bundling immune checkpoint inhibitor negotiations a less costly option for NSCLC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news

Oncotarget: mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
(Impact Journals LLC) All these preclinical data strongly suggest that the inhibition of mTORC1 and PLK1 proteins may be a promising therapeutic approach for NSCLC patients (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 30, 2021 Category: Biology Source Type: news

Top Abstracts in Locally Advanced NSCLC From ASCO 2021 Top Abstracts in Locally Advanced NSCLC From ASCO 2021
Dr Thomas Stinchcombe discusses key data on locally advanced NSCLC from ASCO 2021, including results of atezolizumab as adjuvant therapy and chemotherapy plus immunotherapy in the neoadjuvant setting.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 29, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news

Key Presentations on Advanced NSCLC From ASCO 2021 Key Presentations on Advanced NSCLC From ASCO 2021
Dr Mark A. Socinski highlights studies on advanced NSCLC from ASCO 2021, including data on combination immunotherapy, immune adverse events, and response to sotorasib.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 25, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news

RSNA announces 2021 meeting highlights
The RSNA has announced program highlights ahead of its 2021 annual meeting t...Read more on AuntMinnie.comRelated Reading: RSNA announces MIDRC funding program RSNA R&E grant study identifies new biomarker for NSCLC RSNA plans for in-person meeting in 2021 Top healthcare trends on display at RSNA 2020 FDG-PET/CT within a year of heart valve surgery looks safe (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 24, 2021 Category: Radiology Source Type: news

RSNA announces MIDRC funding program
The RSNA is seeking fund proposals from researchers interested in submittin...Read more on AuntMinnie.comRelated Reading: RSNA R&E grant study identifies new biomarker for NSCLC SIIM, RSNA, others partner on COVID-19 AI challenge RSNA plans for in-person meeting in 2021 MIDRC offers support for COVID-19 AI AMVC Spring 2021: MIDRC project targets AI challenges of COVID-19 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 23, 2021 Category: Radiology Source Type: news

Racism and segregation associated with advanced stage lung cancers among blacks
(Boston University School of Medicine) Lung cancer remains the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for 80-85% cases of lung cancer and when diagnosed early, has a five-year survival rate of 50-80%. Black patients have lower overall incidence of NSCLC than white patients, but are more likely to be diagnosed at later stages. They also are less likely to receive surgery for early-stage cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 22, 2021 Category: Cancer & Oncology Source Type: news

In Early Lung Cancer, Immunotherapy Plus Targeted Radiation May Up Response Rate In Early Lung Cancer, Immunotherapy Plus Targeted Radiation May Up Response Rate
Patients with non-small-cell lung cancer may respond more quickly to neoadjuvant durvalumab combined with stereotactic body radiotherapy than to immunotherapy alone, an early industry-funded trial suggests.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - June 21, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Clinical Trial Shows Benefits of Vinorelbine for Mesothelioma
Mesothelioma specialist Dr. Dean Fennell has strongly endorsed the use of vinorelbine as a second-line treatment for patients with relapsed disease. He was the lead investigator in a recent phase II clinical trial studying the efficacy of vinorelbine for patients whose pleural mesothelioma cancer had progressed after traditional platinum-based chemotherapy. Fennell, who is chair of thoracic and medical oncology at University of Leicester and University Hospitals in the United Kingdom, has based his belief on the multicenter trial involving 154 mesothelioma patients with relapsed disease. “Doctors should now ...
Source: Asbestos and Mesothelioma News - June 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Moffitt develops non-invasive approach to predict outcomes in lung cancer
(H. Lee Moffitt Cancer Center& Research Institute) In a new article published in the Journal for ImmunoTherapy of Cancer, Moffitt Cancer Center researchers show that PET/CT images can be used to measure levels of the PD-L1 biomarker of non-small cell lung cancer (NSCLC) patients in a non-invasive manner and, in turn, predict a patient's response to therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 17, 2021 Category: Cancer & Oncology Source Type: news

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer
FDA granted accelerated approval to capmatinib (TABRECTATM, Novartis) for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves brigatinib for ALK-positive metastatic NSCLC
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations
On Dec. 18, 2020, FDA approved osimertinib (TAGRISSO, AstraZeneca Pharmaceuticals LP) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression
Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

LUMAKRAS (sotorasib), FDA Approved for Treatment of KRAS G12C-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., June 11, 2021 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Amgen Oncology as a specialty pharmacy provider for LUMAKRASTM (sotorasib) for the treatment of patients with KRAS G12C-mutated locally advanced ... (Source: McKesson News)
Source: McKesson News - June 11, 2021 Category: Information Technology Source Type: news

Breath Test Predicts Immunotherapy Response to Mesothelioma
Researchers in the Netherlands are touting a novel breath test for mesothelioma patients to better predict response to the immunotherapy combination of nivolumab and ipilimumab that was approved recently for first-line treatment of the disease. They believe exhaled breath analysis using electronic technology – known as eNose – can differentiate between responders and nonresponders before treatment begins, saving many patients from unnecessary side effects. There currently are no biomarkers for mesothelioma that can accurately predict the effectiveness of these types of immunotherapy drugs, known as immune...
Source: Asbestos and Mesothelioma News - June 10, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer
FDA granted accelerated approval to amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 10, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

ASCO: Sotorasib Targets KRAS p.G12C-Mutated NSCLC
WEDNESDAY, June 9, 2021 -- Sotorasib therapy yields clinical benefit for patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer (NSCLC), according to a study published online June 4 in the New England Journal of Medicine to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 9, 2021 Category: Pharmaceuticals Source Type: news

Targeted therapy pralsetinib safely effectively treats lung and thyroid cancers with RET alterations
(University of Texas M. D. Anderson Cancer Center) Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 9, 2021 Category: Cancer & Oncology Source Type: news

Community Practices Still Not Testing Half of NSCLC Cases Community Practices Still Not Testing Half of NSCLC Cases
Lung cancer patients treated in community practices are not being comprehensively tested for biomarkers that could guide choice of first-line therapy, a recent retrospective analysis shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

NSCLC: Immune-Related AEs May Predict Survival Outcomes NSCLC: Immune-Related AEs May Predict Survival Outcomes
Experiencing an immune-related adverse event during checkpoint inhibitor treatment may predict outcomes in patients with nonsmall cell lung cancer, exploratory analyses of phase 3 trials suggest.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 7, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves First Targeted Therapy for NSCLC With KRAS Mutations
FRIDAY, June 4, 2021 -- Lumakras (sotorasib) received the first approval for a targeted therapy in adults with non-small cell lung cancer with KRAS G12C genetic mutations, the U.S. Food and Drug Administration announced on May 28. KRAS G12C... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2021 Category: Pharmaceuticals Source Type: news

First Phase Results of MYLUNG Consortium Provide Historical View of Biomarker Testing Patterns and Identify Data Gaps for Ongoing Prospective Research
Over 80 percent of non-small cell lung cancer detected at Stage 4Fewer than 50 percent of patients had five or more biomarker testsMedian time from diagnosis to first-line therapy is about five weeks (Source: McKesson News)
Source: McKesson News - June 4, 2021 Category: Information Technology Source Type: news

Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer
(University of Texas M. D. Anderson Cancer Center) Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2021 Category: International Medicine & Public Health Source Type: news

Newly approved drug effective against lung cancer caused by genetic mutation
(Washington University School of Medicine) The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial led by Washington University School of Medicine in St. Louis. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with lung adenocarcinoma, a common type of non-small-cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2021 Category: Cancer & Oncology Source Type: news

Delaying Surgery Linked to Worse Outcomes for NSCLC
WEDNESDAY, June 2, 2021 -- For patients with non-small cell lung cancer (NSCLC), delaying surgical procedures for more than 12 weeks is associated with an increased risk for recurrence and worse survival, according to a study published online May 27... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 2, 2021 Category: Pharmaceuticals Source Type: news

Stereotactic Radiotherapy for Early Stage NSCLC Stereotactic Radiotherapy for Early Stage NSCLC
A new review explores the current role of stereotactic body radiation therapy in the treatment of early stage non-small cell lung cancer and highlights recent research.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news